TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05185752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIFP Block Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by SIFP block: lateral and anterior cutaneous branches of the 2nd-6th Intercostal Nerves.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II block: Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by PECS-II: Lateral Pectoral Nerve and Medial Pectoral Nerve Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block: Locoregional Interfascial Anesthesic Technique
Description: Interfascial blocks emerged as locoregional techniques that incorporate ultrasonography to visualise the anatomy while administrating the drug, reducing the rate of complications. There are multiple locoregional interfascial techniques continue to be implemented; in 2011 Blanco described Pectoral Nerve Block (PECS block); in 2012, Serratus-Intercostal Fascial Plane Block (SIFP) was described, and in 2016, Forero described the Erector Spinae Plane Block (ESP).~Drug: 30 cc 0.25% bupivacaine. Nerves blocked by ESP Block: dorsal and ventral branch block of the spinal nerves; white and gray communicating branches of the sympathetic nerves that go to the thoracic sympathetic chain.~Devices: S-Nerve® ultrasound was used in all three techniques; linear 6 to 13 Megahertz and convex 2 to 5 Megahertz transducers and 22G (Gauge) x 50 mm needles.
Study: NCT02672319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided glue injection
Description: Experimental: EUS-guided glue injection Gastroesophageal varices \> 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
Study: NCT03896763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either supine or prone positioning and either CMV or HFOV
Description: Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either supine or prone positioning and either CMV or HFOV
Description: Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either supine or prone positioning and either CMV or HFOV
Description: Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Either supine or prone positioning and either CMV or HFOV
Description: Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver.
Study: NCT00086515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin (MK0431)
Description: Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Glipizide 5 mg
Description: Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
Study: NCT03987620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Ibrexafungerp 300mg BID for one day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT00086515

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period \[Phase A\], from Visit 5 (Week 6) to Visit 8 (Week 24)
Study: NCT02495883

Intervention type: OTHER
Group type: OTHER
Intervention: Ethanol
Description: 50ml of 40% Ethanol

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol
Description: Beta blocker
Study: NCT00400140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperopic lens
Description: +3 D glasses
Study: NCT03539679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encouraging physical activity.
Description: Encouraging physical activity with motion sensor's feedback.
Study: NCT00737360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-106
Description: 6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT01911260

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc amino acid chelate
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc amino acid chelate
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Study: NCT03270995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Existential Therapy Group 1
Description: Six group sessions of two hour each using a cognitive-existential group approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy Group 2
Description: Six group session of two hour each using a supportive group approach.
Study: NCT03236545

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No to Low Endogenous Estrogen
Description: Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No to Low Endogenous Estrogen
Description: Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
Study: NCT03802019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNC Cigarettes + Colored Packaging
Description: After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNC Cigarettes + Colored Packaging
Description: After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNC Cigarettes + Colored Packaging
Description: After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LNC Cigarettes + Colored Packaging
Description: After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own Brand
Description: After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
Study: NCT03925467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21.
Study: NCT00741377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHQ880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study: NCT00209131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax
Description: 0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
Study: NCT05728021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record Aftercare
Description: Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
Study: NCT02401022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD8529
Description: comparison of different dosages of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD8529
Description: comparison of different dosages of drug
Study: NCT03477136

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
Study: NCT03417323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression
Description: Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
Study: NCT03117920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
Study: NCT02043080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Tuberculosis diagnostic tool
Description: This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
Study: NCT00651391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral simvastatin 20 mg once daily in the evening for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily in the evening for 12 weeks
Study: NCT02564497

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Process E Belatacept

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Process C Belatacept
Study: NCT02904993

Intervention type: OTHER
Group type: OTHER
Intervention: L2 paravertebral block
Description: nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periarticular injection group
Description: periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
Study: NCT01518348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patch Test
Description: Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
Study: NCT03918148

Intervention type: DRUG
Intervention: SGLT-2i
Description: Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin

Intervention type: DRUG
Intervention: DPP-4i
Description: Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
Study: NCT02949700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
Study: NCT04128085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3804
Description: A kind of tyrosine kinase inhibitor.